reviewing-treatment-protocols

name	reviewing-treatment-protocols
description	Evaluates NCCN guideline-concordant treatment plans with evidence levels and alternatives. Use when reviewing cancer treatment plans, checking NCCN compliance, or evaluating treatment options.
tags	["review","oncology","compliance","treatment"]
metadata	{"author":"casemark","practice_areas":["Medical Oncology","Hematology-Oncology","Radiation Oncology"],"document_types":["Review Report"],"skill_modes":["Review","Analysis"]}

Reviewing Treatment Protocols

Evaluates NCCN guideline-concordant treatment plans with evidence levels and alternatives.

Why This Skill Exists

Guideline concordance in oncology treatment directly correlates with survival outcomes. NCCN Clinical Practice Guidelines are updated multiple times per year and represent the consensus of 32 NCI-designated comprehensive cancer centers. Payer prior authorization increasingly references NCCN compendia for coverage decisions. Deviation from Category 1 or 2A recommendations without documented rationale exposes institutions to liability, denial of coverage, and potential adverse patient outcomes.

CMS Oncology Care Model (OCM) and successor value-based programs require demonstrated adherence to evidence-based pathways. CoC accreditation surveys evaluate concordance rates. ASCO Quality Oncology Practice Initiative (QOPI) uses guideline adherence as a core quality metric. This skill ensures treatment plans are systematically evaluated against current NCCN guidelines with documented evidence levels for every recommendation.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the cancer type, stage, and histologic subtype? (Default: [VERIFY] — must be specified)
2. What is the patient's current ECOG performance status? (Default: 0–1)
3. Has biomarker/molecular testing been completed? If yes, provide results. (Default: pending)
4. What line of therapy is being reviewed (first-line, second-line, etc.)? (Default: first-line)
5. Are there relevant comorbidities affecting treatment selection? (Default: none documented)
6. Which NCCN guideline version is current for this cancer type? (Default: most recent version)
7. Is the patient being considered for a clinical trial? (Default: no)
8. What is the treatment intent — curative, adjuvant, neoadjuvant, or palliative? (Default: specify)

Documents to Request

• Current NCCN guideline version for the specific cancer type
• Complete staging workup documentation
• Molecular and biomarker test results (PD-L1, MSI, TMB, driver mutations)
• Pathology report with histologic grade and subtype
• Prior treatment history with response and toxicity documentation
• Organ function labs (renal, hepatic, cardiac, hematologic)
• Imaging reports establishing baseline disease burden
• Insurance authorization requirements or formulary restrictions

---

Step 1: Verify Diagnosis Classification and Guideline Mapping

Confirm the diagnosis maps to the correct NCCN guideline. Many cancers have distinct guidelines by subtype:

Cancer Type	Separate NCCN Guidelines
Lung	Non-small cell (NSCLC) vs. Small cell (SCLC)
Breast	Invasive vs. DCIS; further split by ER/PR/HER2
Lymphoma	Hodgkin vs. B-cell vs. T-cell vs. Primary cutaneous
Kidney	Renal cell (clear cell vs. non-clear cell)
Leukemia	AML vs. ALL vs. CLL vs. CML (each has own guideline)

Verify the proposed treatment falls within the correct guideline decision pathway node. Trace the algorithm from diagnosis through biomarker status to the specific treatment recommendation.

---

Step 2: Evaluate Treatment Recommendation Against NCCN Categories of Evidence

NCCN categories of evidence and consensus:

Category	Definition
1	High-level evidence + uniform NCCN consensus
2A	Lower-level evidence + uniform NCCN consensus (most recommendations)
2B	Lower-level evidence + non-uniform NCCN consensus
3	Any level evidence + major NCCN disagreement

For each component of the proposed treatment plan, document:

• The specific NCCN recommendation and its evidence category
• Whether the recommendation is "preferred," "other recommended," or "useful in certain circumstances"
• The guideline version and page/node reference
• Whether biomarker-directed therapy is indicated and correctly selected

Flag any regimen not found in the current NCCN guideline as "off-pathway" and require documented justification.

---

Step 3: Assess Dose, Schedule, and Supportive Care Compliance

Review the proposed regimen for:

• Dose accuracy: Verify mg/m² or mg/kg calculations against NCCN-specified doses. Common error: using flat dosing where weight-based is specified (e.g., pembrolizumab 200mg flat vs. 2mg/kg).
• Schedule concordance: Confirm cycle length, treatment days, and total planned cycles match guideline recommendations.
• Supportive care: Verify appropriate antiemetic regimen per NCCN Antiemesis guidelines (high vs. moderate vs. low emetogenic potential). Confirm G-CSF prophylaxis for regimens with >20% febrile neutropenia risk per NCCN Hematopoietic Growth Factors guideline.
• Pre-medications: Confirm required premedications (e.g., dexamethasone for taxanes, acetaminophen/diphenhydramine for rituximab).
• Monitoring requirements: Verify mandated monitoring (e.g., LVEF for trastuzumab, LFTs for checkpoint inhibitors, EKG for certain TKIs).

---

Step 4: Document Alternatives and Deviations

For each treatment component:

1. List NCCN-preferred alternatives at the same decision node
2. If the proposed treatment deviates from preferred options, document the rationale category:
   • Patient comorbidity (specify organ dysfunction or interaction)
   • Prior treatment history (progression on preferred agent)
   • Molecular profile directing alternative selection
   • Patient preference with informed consent documentation
   • Clinical trial enrollment
   • Drug availability or access limitation
3. Rate the deviation severity: minor (within guideline options), moderate (guideline-listed but not recommended for this node), major (not in current guideline)

---

Step 5: Generate Concordance Summary Report

Structure the final review as:

1. Concordance determination: Concordant / Concordant with minor deviation / Non-concordant
2. Evidence level for each treatment component with NCCN category
3. Identified gaps: Missing biomarker testing, incomplete staging, unsupported dose modifications
4. Alternative recommendations ranked by evidence level
5. Required actions before treatment initiation (e.g., complete HER2 testing, obtain cardiac clearance)
6. Payer considerations: Note if the regimen qualifies for NCCN Compendium coverage or requires prior authorization with clinical rationale

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Does the review reference the current NCCN guideline version (not an outdated edition)?
2. Are all NCCN evidence categories correctly cited for each recommendation?
3. Have all guideline-required biomarker tests been verified as completed or flagged as pending?
4. Are dose modifications and supportive care reviewed against relevant NCCN supportive care guidelines?
5. Is the concordance determination clearly stated with supporting rationale?

---

Quality Audit

• Correct NCCN guideline identified for cancer type and subtype
• Guideline version number and date documented
• Treatment mapped to specific algorithm decision node
• Evidence category (1, 2A, 2B, 3) cited for each recommendation
• Preferred vs. other recommended vs. useful in certain circumstances distinction documented
• Dose accuracy verified against guideline-specified regimen
• Cycle schedule and duration match guideline recommendations
• Required biomarker testing confirmed complete or flagged
• Supportive care (antiemetics, G-CSF, premedications) evaluated
• Treatment deviations documented with rationale category
• Alternative regimens listed with evidence levels
• Payer coverage implications noted
• Concordance determination clearly stated
• No references to superseded guideline versions

---

Guidelines

• Always reference the most current NCCN guideline version — guidelines are updated multiple times per year
• Never assume a regimen is concordant without tracing the algorithm from diagnosis through biomarkers to the specific treatment node
• NCCN Category 2A is the default for most recommendations — absence of a category label means 2A
• "Preferred" designation is stronger than "other recommended" and should be the default recommendation
• Off-label use of approved drugs must still be evaluated for NCCN Compendium listing for coverage purposes
• Document whether the treatment intent (curative vs. palliative) aligns with the stage and guideline pathway
• Flag any regimen that lacks NCCN listing — this is a major payer coverage risk
• When multiple equivalent options exist, note patient-specific factors that favor one over another